Loading organizations...
Loading organizations...
Epirium Bio: Clinical-stage biopharmaceutical company developing small molecule drugs to stimulate mitochondrial biogenesis for rare diseases.
Epirium Bio is a clinical-stage biopharmaceutical company developing small molecule drugs to treat rare diseases linked to mitochondrial dysfunction, and is based in San Diego, California. The organization's proprietary platform focuses on stimulating mitochondrial biogenesis and function to address severe neuromuscular conditions, specifically targeting Becker and Duchenne muscular dystrophy. Its lead therapeutic candidate, EPM-01, is currently advancing through Phase 1 clinical trials to evaluate safety and initial efficacy. To support this clinical pipeline, the private biotech enterprise secured $85 million in Series A financing from a syndicate of prominent healthcare investors. This significant funding round was co-led by Longitude Capital and ARCH Venture Partners, with additional participation from Bluebird Ventures. Operating under the leadership of Chief Executive Officer Alexander Casdin, the company was founded in 2017 by George Schreiner, Sundeep Dugar, and Russell Cox.
Epirium Bio has raised $85.0M across 1 funding round.
Epirium Bio has raised $85.0M in total across 1 funding round.
Epirium Bio has raised $85.0M in total across 1 funding round.
Epirium Bio's investors include ARCH Venture Partners, Adams Street Partners, Jeff Bird, Longevity Fund, Patrick Enright, Vertex Ventures HC.
Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics that inhibit 15-PGDH to elevate PGE2 levels, promoting mitochondrial biogenesis, muscle regeneration, and tissue repair for neuromuscular and neurodegenerative diseases.[1][2][4] It targets unmet needs in conditions like sarcopenia, Becker and Duchenne muscular dystrophy, spinal muscular atrophy, and potentially idiopathic pulmonary fibrosis, with its lead candidate MF-300 (formerly EB-002 or EPM-01) in Phase 1 trials for sarcopenia, showing preclinical reversal of age-related muscle weakness.[3][4][6] Backed by investors including Arch Venture Partners, Longitude Capital, and The Longevity Fund, Epirium demonstrates growth through IP-protected platforms, 19 patents, and advancing clinical programs amid rising demand for muscle rejuvenation therapies.[3][4][7]
Epirium Bio, based in San Diego, California, traces its roots to 2008 as Cardero Therapeutics before rebranding to focus on its current platform; it formally advanced as a clinical-stage entity around 2017 with founders George Schreiner, Sundeep Dugar, and Russell Cox bringing expertise in biopharma and mitochondrial biology.[3][4] The idea emerged from unique insights into mitochondrial biogenesis and PGE2 signaling, sparked by preclinical data showing 15-PGDH inhibition enhances muscle stem cell differentiation, mitochondrial function, and tissue regeneration—pivotal for diseases like muscular dystrophies.[1][2][5] Early traction included IP establishment, Series A funding from longevity-focused VCs, and progression to Phase 1 trials for Becker muscular dystrophy (EB-002) and sarcopenia (MF-300), with topline Phase 1 results anticipated in the second half of 2025.[1][3][4]
Epirium rides the wave of mitochondrial medicine and longevity biotech, targeting cellular energy deficits underlying age-related muscle loss (sarcopenia affecting 50M+ globally) and rare neuromuscular disorders amid a $100B+ neuromuscular market.[2][3][4] Timing aligns with aging populations, post-2020 inflammation research surges (e.g., PGE2 in tissue repair per Science 2021), and VC influx into small-molecule platforms reversing degeneration rather than symptom management.[5][7] Market forces like unmet needs in Duchenne/Becker MD (no curative therapies) and sarcopenia (projected $10B market by 2030) favor Epirium, while its longevity investor ties amplify influence in the ecosystem, fostering cross-indication data for fibrosis and neurodegeneration.[1][3][6]
Epirium's Phase 1 readouts for MF-300 in H2 2025 will be pivotal, potentially unlocking Phase 2 in sarcopenia and rare diseases like Becker MD, with preclinical assets in SMA and IPF expanding the pipeline.[4][6] Trends in AI-driven drug discovery, PGE2 modulation, and combo therapies for mitochondrial disorders will accelerate its trajectory, positioning it as a leader in muscle regeneration biotech. As mitochondrial insights deepen, Epirium could evolve from rare disease pioneer to broad rejuvenation player, delivering first-in-class therapies that restore tissue vitality where none exist today—echoing its core mission to tackle intractable neuromuscular challenges.[1][2][5]
Epirium Bio has raised $85.0M across 1 funding round. Most recently, it raised $85.0M Series A in December 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2019 | $85.0M Series A | ARCH Venture Partners, Adams Street Partners, Jeff Bird, Longevity Fund, Patrick Enright, Vertex Ventures HC |